Trials / Unknown
UnknownNCT04192682
Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Changzhou Cancer Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Immunotherapy combined with anti-angiogenic therapy can achieve better results in patients with second-line and above small cell lung cancer
Detailed description
Through this study, it was found that Anlotinib combined with Sintilimab has a better survival benefit. At the same time, genetic analysis and immunohistochemical methods have been used to predict the predictive value of targeted therapy combined with Sintilimab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib Hydrochloride | Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。 |
Timeline
- Start date
- 2019-05-08
- Primary completion
- 2021-03-01
- Completion
- 2021-07-01
- First posted
- 2019-12-10
- Last updated
- 2020-01-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04192682. Inclusion in this directory is not an endorsement.